Enfuvirtide

Medical Advocates
Enfuvirtide [T-20] (Fuzeon)

Conference Citations

19th CROI
17th CROI
16th CROI
XVII International AIDS Conference
15th CROI
4th IAS Conference
14th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
Conference Archives

Enfuvirtide Main Page Main New/Newsworthy Home Page

Last Update: December 08, 2014

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

19th Conference on Retroviruses and
Opportunistic Infections

POSTER
Decrease in Inflammatory and Coagulation Biomarkers in HIV⁺ Patients after Switching from Enfuvirtide to Raltegravir: The Randomized ANRS 138 EASIER Trial
E Silva, I Charreau, B Gourmel, et al
PDF Poster     Abstract

6th International AIDS Society (IAS) Conference on
HIV Pathogenesis, Treatment and Prevention

POSTER
Evaluation of mutations related to fusion inhibitors in GP41 in patients with HIV-1 on antiretroviral therapy
M. Medeiros, C. Brown, J. Maciel. et al
Poster     Abstract

POSTER
Study of resistance mutations and polymorphisms in the RRE region of gp41 from HIV-1 naīve patients and
in use of antiretroviral therapy
M. Medeiros, C. Brown, J. Maciel, et al
Poster     Abstract

POSTER
Evaluation of viral replication and cytopathic effects from mutation in codon 36 in HIV-1 pNL4-3 derivate virus
M. Medeiros, D. Shuck-Lee, E. Arruda, et al
Poster     Abstract

Binding of enfuvirtide to human red blood cells resulting in the decreased anti-HIV activity of enfuvirtide
L. Lu, S. Tan, S. Jiang I
Abstract

Susceptibility of HIV-1 subtypes B´, CRF07_BC and CRF01_AE that are predominantly circulating in China
to HIV-1 entry inhibitors
X. Yu, L. Yuan, W. Xu, et al
Abstract

Optimizing enfuvirtide use through rational use of new antiretroviral regimens
H. Bernal, R. Hallal
Abstract

17th Conference on Retroviruses and
Opportunistic Infections

POSTER
Intensification of HAART through the Addition of Enfuvirtide in Naive HIV-infected Patients with
Severe Immunosuppression Does Not Improve Immunological Response: Results of a Prospective
Randomized Multicenter Trial (APOLLO - ANRS 130)
V Joly, C Fagard, D Descamps, et al
PDF Poster   Abstract

POSTER
Relative Replicative Fitness of HIV-1 Mutants Resistant to Enfuvirtide
N Kim, Z Hu, F Giguel, D Kuritzkes
PDF Poster   Abstract

16th Conference on Retroviruses and
Opportunistic Infections

POSTER
No Evidence for Decay in the Latent Reservoir in HIV-infected Patients Receiving Intensive Enfuvirtide-containing ART
R Gandhi, R Bosch, E Aga 1
PDF Poster     Abstract

XVII International AIDS Conference

Improvement and prevention of enfuvirtide injection site reactions (ISR) with topical hyperoxygeneated
fatty acids (HFA)
E. Pedrol, I. Vidal, P. García, E. Deig
Abstract

Baseline susceptibilities of enfuvirtide against HIV-1 subtype C CCR5 and CXCR4-utilizing primary isolates
M. Killick, G. Napier, A. Capovilla, et al
Abstract

Is bacterial pneumoniae occurrence increased among enfuvirtide-containing cART treated patients?
I. Kousignian, O. Launay, C. Mayaud, et al
Abstract

15th Conference on Retroviruses and
Opportunistic Infections

POSTER
Use of Enfuvirtide in HIV⁺ Pregnant Women
A Haberl, R Linde, A Reitter, et al
PDF Poster     Abstract

Effect of Different Enfuvirtide-resistance Mutations on Variability of the Rev Responsive Element
and the rev Gene in Patients on Enfuvirtide Treatment
E Poveda, M Gonzalez, V Briz, et al
PDF Poster     Abstract

Enfuvirtide Therapy Increases Naīve and Central Memory CD4 T Cells, Decreases the Level
of Immune Activation and Apoptosis
H Carsenti Dellamonica, J Durant, M Ticchioni, et al
Abstract

Immunological Success Is Predicted by Enfuvirtide but Not Interleukin-2 in Immunocompromised
Patients, Final Results of the ANRS 123 ETOILE Randomized Trial
J-P Viard, C Fagard, C Rouzioux, et al
Abstract

The Pressure Imposed by T-20 Selects Mutations also in the Regulatory Protein Rev
V Svicher, R D'Arrigo, C Alteri
Abstract

4th International AIDS Society (IAS) Conference on
HIV Pathogenesis, Treatment and Prevention

Viral load decay in advanced naīve patients treated with enfuvirtide based HAART: a pilot
randomised controlled study
Castagna A, Danise A, Cattelan AM, et al
Abstract

A randomised study to evaluate injection site reactions (ISR) using three different mechanisms
for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device
Boyd M, Truman M, Hales G, et al
Abstract

Recovery of anti-JCV specific T cell responses and better survival on intensified antiretroviral
therapy in HIV-1 infected patients with progressive multifocal leukoencephalopathy: the
ANRS 125 trial
Gasnault J, Hendel Chavez H, Darasteanu I, et al
Abstract

The prevalence of resistant mutations to enfuvirtide in antiretroviral naive HIV-1 infected
patients
Chew CB, Shah M, Wang B, Shaw CO, et al
Abstract

French observatory of HIV-1 infected patients experiencing virological failure while receiving enfuvirtide
salvage antiretroviral therapy containing regimen
Descamps D, Assoumou L, Masquelier B, et al
Abstract

14th Conference on Retroviruses and
Opportunistic Infections

POSTER
Enfuvirtide Does Not Require Dose-adjustment in Patients with Chronic Renal Failure: The Results
of a Pharmacokinetic Study of Enfuvirtide in HIV-1-infected Patients with Impaired Renal Function
(NP17586)
P Tebas, N Bellos, C Lucasti, et al
PDF Poster   Abstract
POSTER
Lack of Placental Transfer of Enfuvirtide in an ex vivo Human Placental Cotyledon Perfusion Model
Ferreira, P Ceccaldi, B Visseaux, et al
PDF Poster    Abstract
POSTER
CCR5 Density Levels on Primary CD4 T Cells Affect the Replication and Enfuvirtide Susceptibility of
R5 HIV-1: Clinical Implications
A Heredia, B Gilliam, O Latinovic, et al
PDF Poster    Abstract
POSTER
Kinetics of Disappearance of Enfuvirtide-resistance HIV-1 Mutations after Drug Discontinuation
C Charpentier, M Jenabian, C Piketty, et al
PDF Poster    Abstract

8th Int Congress on Drug Therapy in HIV Infection

A pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID) enfuvirtide (ENF)
D Wright, A Rodriguez, E Godofsky, et al
Abstract
Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20)
M Vogel, E Wolf, K Ummard, et al
Abstract
Evaluation of the local tolerance and quality of life in 60 HIV-1 infected patients treated with an
ARV regimen containing enfuvirtide: SURCOUF cohort
C Allavena, T Prazuck, G Le Moal, et al
Abstract
Prospective study assessing injection site reactions, quality of life and enfuvirtide administration
preference using Biojector versus needles
M Loutfy, M Harris, J Raboud, et al
Abstract
Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent active mycobacterial
infection: a pilot experienceInter-country variation in physician perspectives of enfuvirtide (ENF)
prescribing
R Horne, V Cooper, G Gellaitry
Abstract
Switching a toxicity-causing antiretroviral (ARV) to enfuvirtide (ENF) in patients with treatment-
limiting toxicities
M Stoll, M Muller, S Staszewski, et al
Abstract

Mitochondrial DNA (mtDNA) content in enfuvirtide-treated healthy volunteers
G Garrabou, S Lopez, V Rodriguez, et al
Abstract

XVI International AIDS Conference

Patients and physicians attitudes and perceptions towards oral versus subcutaneous
Highly Active antiretroviral Therapy (HAART)
C Rodríguez Fumaz, H Knobel Freud, A Segador Gķmez, et al
Abstract
Long-term efficacy of enfurvitide - the RADATA-Fuzeon cohort
C Hoffmann , T Lorenzen , K Arasteh, et al
Abstract
Discontinuation of enfuvirtide after long-term administration in HIV-1-infected patients
the Swiss HIV cohort study (SHCS)
L Elzi, G Kaufmann, R Weber, et al
Abstract
Combination of TMC114/ritonavir and TMC125 in patients with multidrug resistant HIV
J Montaner , M. Harris 1, G. Larsen , et al
Abstract
TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis
JM Molina, C Cohen, C Katlama, et al
Abstract
Design of a novel peptidic HIV-1 fusion inhibitor against drug-resistant viruses
J Chen Y He , M. Dong
Abstract
Analysis of cost of full virologic suppression for treatment-experienced, HIV-infected patients
A Hill, C Smith
Abstract
Absence of TMC114 exposure-efficacy and exposure-safety relationships in power 3
V Sekar, S De Meyer, T Vangeneugden,
Abstract
Injectable therapy in HIV: the role of physician and patient attitudes
R Horne, V Cooper, C Tsoukas
Abstract

Prevalence of GP41 resistance-associated mutations and polymorphism in naive patients:
analysis of 1703 HIV-1 sequences over a 20 years period
AAN Al Hawajr, C Alloui, E Gault, et al
Abstract
Success of rescue therapy with TMC114 in HIV-infected patients who failed multiple
ritonavir-boosted protease inhibitor-based regimens
E Poveda, F Blanco, P García-Gasco, et al
Abstract
Positive patient adherence and satisfaction using a novel nursing support program as part of
enfuvirtide therapy
E. Sweeney, N. Johnson, M. DeSpirito, B. Greer
Abstract
Does enfuvirtide perception change when patients used it?
N. Terrail, S. Guessant, V. Dubois, et al
Abstract
Discontinuation of enfuvirtide after long-term administration in HIV-1-infected patients the Swiss
HIV cohort study (SHCS)
L. Elzi, G. Kaufmann, R. Weber, ., et al
Abstract
CD4 increases in patients with ongoing viral replication while receiving enfuvirtide are associated
with V38 and other mutations in gp41
T. Melby, M. DeSpirito, R. Demasi, G., et al
Abstract
Quality of life (Qol) and tolerability after administration of enfuvirtide (ENF) with a 31-Gauge,
thin-walled, 8mm needle (QUALITE study)
P. Shalit, A. True, J. Thommes, et al
Abstract
Currently marketed nucleos(t)ides provide only marginal additional viral load (VL) suppression to
regimens including enfuvirtide (ENF) and boosted PIs (PI/r) in triple class experienced patients
(TEPs)
R. DeMasi, J. Thommes, N. Graham, et al
Abstract
Evolution of genotyping and phenotyping resistance to enfuvirtide in HIV-infected patients with
persistent viraemia, during and after treatment
M.-A. Trabaud, L. Cotte, J.L. Labernardičre, et al
Abstract
A nonrandomized large prospective evaluation of alternative injection devices (BiojectorŽ 2000
(B2000), standard needles/syringes, or insulin needles/syringes) for enfuvirtide (ENF) in a national
community-based specialty pharmacy
S. Tschida, A. Zappa, M. Godwin, et al
Abstract
The mechanism of enfuvirtide resistance and structural insights into the corresponding fitness
deficits in response to the N43D resistance mutation
X. Bai, J. Seedorff, K. Wilson, et al
Abstract

Enfuvirtide Main Page Main New/Newsworthy Home Page

Enfuvirtide Conference Citations